Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 46Unknown 7Terminated 4Recruiting 4Approved for marketing 3Withdrawn 1Suspended 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 33Pemetrexed 25Cisplatin 23Paclitaxel 20Radiotherapy 16Docetaxel 16Gemcitabine 15durvalumab 14Radiosurgery 14pembrolizumab 13Nivolumab 13Erlotinib Hydrochloride 10Taxes 8atezolizumab 7Magnetic Resonance Spectroscopy 7Drug Therapy 6Cyclophosphamide 6Bevacizumab 6Platinum 5Gefitinib 5130-nm albumin-bound paclitaxel 5Etoposide 4Biopsy 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3sotorasib 3poly ICLC 3capmatinib 3Surveys and Questionnaires 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Non-Small-Cell Lung × Afatinib × Clear all
NCT01836341 2013-12-19

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Memorial Sloan Kettering Cancer Center

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡